Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 931 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Orthomyxoviridae Infection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

NCT01405885
View directory record Official record
Conditions
Healthy
Interventions
INO-3605, INO-3609, INO-3401, INO-3605 AND INO-3609, INO-3510, Seasonal Influenza vaccine
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 15, 2026, 3:42 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A/Texas Flu Challenge

NCT06753474
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus influenza A H3N2 strain
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 15, 2026, 3:42 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00835926
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 15, 2026, 3:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting

NCT00828555
View directory record Official record
Conditions
Influenza Vaccine, Papillomavirus Infection, Pertussis
Interventions
Vaccination Program
Other
Lead sponsor
Duke University
Other
Eligibility
12 Years to 26 Years · Female only
Enrollment
3,988 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
4
States / cities
Burlington, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

NCT05436444
View directory record Official record
Conditions
Influenza Infection
Interventions
A/Mallard/Ohio-99/MM4/1989 H10N7
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Vaccine for Prevention of Bird Flu

NCT00776711
View directory record Official record
Conditions
Influenza, Human
Interventions
Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005, VRC-AViDNA036-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

NCT04074928
View directory record Official record
Conditions
Influenza, Human, Virus Diseases
Interventions
QIVc, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 47 Months
Enrollment
2,414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
47
States / cities
Mobile, Alabama • Anaheim, California • Downey, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

NCT01086657
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 3:42 PM EDT
Suspended Phase 3 Interventional

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

NCT00828100
View directory record Official record
Conditions
Influenza
Interventions
fluID Rapid Influenza Test, BinaxNOW® Influenza A & B
Device
Lead sponsor
Nanogen, Inc.
Industry
Eligibility
Not listed
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Shreveport, Louisiana • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 6, 2009 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

NCT01825200
View directory record Official record
Conditions
Influenza
Interventions
Flublok, Afluria
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
2,640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
14
States / cities
Tucson, Arizona • Coral Gables, Florida • Savannah, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

NCT00963157
View directory record Official record
Conditions
Influenza
Interventions
AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
7
States / cities
Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist

NCT00231907
View directory record Official record
Conditions
Influenza
Interventions
FluMist, Fluzone
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 35 Months
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

NCT02839330
View directory record Official record
Conditions
Avian Influenza
Interventions
aH5N1c, Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 15, 2026, 3:42 PM EDT
Recruiting No phase listed Observational

COVID-19 Coagulopathy Extension Study

NCT05334615
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Response to Influenza Vaccine During Pregnancy

NCT03888989
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Completed No phase listed Observational Results available

Influenza Resistance Information Study

NCT00884117
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
4,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

NCT00402649
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 10 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

NCT00992433
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza H1N1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 15, 2026, 3:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Safety and Immunogenicity of NasoVAX Extension

NCT03760549
View directory record Official record
Conditions
Influenza
Interventions
Subjects were administered NasoVAX high dose
Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

NCT06179446
View directory record Official record
Conditions
Grippe, Influenza, Vaccines
Interventions
pdmFlu vaccine, Placebo, Licensed influenza vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 84 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Hollywood, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Memory for Flu Facts and Myths and Effects on Vaccine Intentions

NCT00296270
View directory record Official record
Conditions
Influenza Vaccines
Interventions
Memory for truth
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 26 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2006 · Synced Oct 15, 2026, 3:42 PM EDT